Gergen Mark J 4
4 · Poseida Therapeutics, Inc. · Filed Nov 27, 2024
Insider Transaction Report
Form 4
Gergen Mark J
DirectorExecutive Chairman
Transactions
- Sale
Common Stock
2024-11-26$9.27/sh−30,000$278,100→ 651,291 total - Exercise/Conversion
Common Stock
2024-11-26$2.78/sh+30,000$83,430→ 681,291 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-11-26−30,000→ 126,372 totalExercise: $2.78Exp: 2028-03-01→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024.
- [F2]The stock option is fully vested and exerciseable.